AMLX Stock Overview
A commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Amylyx Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.68 |
| 52 Week High | US$26.44 |
| 52 Week Low | US$1.65 |
| Beta | -0.68 |
| 1 Month Change | -12.95% |
| 3 Month Change | -91.02% |
| 1 Year Change | -93.33% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -90.70% |
Recent News & Updates
Recent updates
Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop
Apr 25
Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically
Mar 12An ALS Drug Fails Again
Mar 09Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications
Feb 23Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues
Feb 23Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper
Nov 10Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business
Sep 24This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year
May 16Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business
Apr 20Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates
Mar 16Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Good Position To Deliver On Growth Plans
Dec 19Amylyx Pharmaceuticals prices $214.2M upsized stock offering at $32.00/share
Oct 07Amylyx ALS Drug Approval: Unexpected, Welcome, And Conditional - May Put Share Price In Stasis
Sep 30Amylyx Pharma stock surges 81% after ALS drug gets FDA advisers backing
Sep 08Amylyx plunges 28% after FDA briefing documents on ALS drug
Sep 02We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate
Aug 29Amylyx Pharmaceuticals GAAP EPS of -$0.93 misses by $0.01
Aug 11Amylyx Pharmaceuticals says ALS treatment Albrioza now available in Canada
Jul 29Amylyx partners with Sunnybrook Research to identify neurodegenerative disease candidates
Jul 18Amylyx: Thoughts Ahead Of September 29 PDUFA In Amyotrophic Lateral Sclerosis
Jul 04Amylyx Pharmaceuticals: Share Price Bump On Canada Approval For ALS Drug May Not Last
Jun 17We're Keeping An Eye On Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate
May 07Amylyx: Crucial Advisory Committee Meet Tomorrow, Approval Chancy
Mar 29Shareholder Returns
| AMLX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -2.9% | -0.8% | -1.2% |
| 1Y | -93.3% | 14.8% | 21.5% |
Return vs Industry: AMLX underperformed the US Pharmaceuticals industry which returned 16.7% over the past year.
Return vs Market: AMLX underperformed the US Market which returned 25.2% over the past year.
Price Volatility
| AMLX volatility | |
|---|---|
| AMLX Average Weekly Movement | 24.7% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: AMLX's share price has been volatile over the past 3 months.
Volatility Over Time: AMLX's weekly volatility has increased from 15% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 384 | Josh Cohen | amylyx.com |
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company’s products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases.
Amylyx Pharmaceuticals, Inc. Fundamentals Summary
| AMLX fundamental statistics | |
|---|---|
| Market cap | US$114.25m |
| Earnings (TTM) | -US$71.09m |
| Revenue (TTM) | US$398.00m |
0.3x
P/S Ratio-1.6x
P/E RatioIs AMLX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMLX income statement (TTM) | |
|---|---|
| Revenue | US$398.00m |
| Cost of Revenue | US$265.57m |
| Gross Profit | US$132.43m |
| Other Expenses | US$203.52m |
| Earnings | -US$71.09m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.05 |
| Gross Margin | 33.27% |
| Net Profit Margin | -17.86% |
| Debt/Equity Ratio | 0% |
How did AMLX perform over the long term?
See historical performance and comparison